Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis
On August 25, 2023,Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko®.
August 28, 2023
by PharmaSources
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.
July 24, 2023
by PharmaSources
Saol Therapeutics Announces FDA Approval of LYVISPAH™ (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio
Saol Therapeutics announced that the FDA has approved Saol's LYVISPAH™ (baclofen) oral granules.
December 9, 2021
by AmericanPharmaceuticalReview
Christina Applegate Announces She Has Multiple Sclerosis
Emmy award-winning actress Christina Applegate revealed Monday night that she is battling multiple sclerosis.
August 11, 2021
by drugs
Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology
QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of ...
June 16, 2021
by prnasia
World Brain Day 2021 Dedicated to Multiple Sclerosis
The World Federation of Neurology (WFN) is pleased to announce that the theme of this year's World Brain Day is Stop Multiple Sclerosis.
May 20, 2021
by prnasia
UK launch for progressive multiple sclerosis mega-trial
The MS Society had announced that a world-first mega-trial for progressive multiple sclerosis (MS) will be launched in the UK later this year.
May 8, 2021
by pharmatimes
Novartis bags EU, UK licences for MS therapy Kesimpta
Novartis has received green lights from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab).
April 9, 2021
by pharmatimes
Emerald Health Starts Activities for Initiation of Phase 2 Clinical Study in Multiple Sclerosis
Emerald Health Pharmaceuticals (EHP) has initiated activities for a Phase 2 international clinical study for the treatment of patients with multiple sclerosis (MS).
March 11, 2021
by americanpharmaceuticalreview
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive MS
Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen.
December 16, 2020
by expresspharma
Multiple sclerosis trial focusing on people who can’t walk begins recruitment
A new trial focusing solely on multiple sclerosis patients who can’t walk is set to begin recruiting participants.
November 20, 2020
by pharmatimes
GW Pharma begins recruitment for US-based Sativex trial
GW Pharmaceuticals has initiated the first US phase III clinical trial studying nabiximols for multiple sclerosis (MS) associated spasticity.
November 6, 2020
by pharmatimes